TY - JOUR
T1 - Impact of postoperative radiotherapy on recurrence of primary intracranial atypical meningiomas
AU - Keric, Naureen
AU - Kalasauskas, Darius
AU - Freyschlag, Christian F.
AU - Gempt, Jens
AU - Misch, Martin
AU - Poplawski, Alicia
AU - Lange, Nicole
AU - Ayyad, Ali
AU - Thomé, Claudius
AU - Vajkoczy, Peter
AU - Meyer, Bernhard
AU - Ringel, Florian
N1 - Publisher Copyright:
© 2020, Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2020/1/1
Y1 - 2020/1/1
N2 - Background: Atypical meningiomas (WHO grade II) have high recurrence rate. However, data on the effect of radiotherapy (RT) is still conflicting. The aim of this study was to evaluate the influence of postoperative RT on the recurrence of primary atypical intracranial meningiomas. Methods: The medical records of all patients who underwent surgery (2007–2017 in 4 neurosurgical departments) for a histologically diagnosed primary atypical meningioma were reviewed to assess progression-free survival (PFS) and prognostic factors. Results: This analysis included 258 patients with a median age of 60 years (54.7% female). The predominant tumor locations were convexity and falx (60.9%) followed by the skull base (37.2%). Simpson grade I–II resection was achieved in 194 (75.2%) patients, Simpson grade III–IV in 53 patients (20.5%). Tumor progressed in 54 cases (20.9%). Postoperative RT was performed in 46 cases (17.8%). RT was more often applied after incomplete resection (37.7% vs. 13.4% Simpson III–IV vs. I–II). A multivariate analysis showed a significantly shorter PFS associated with Simpson III–IV [HR 1.19, (95% CI) 1.09–1.29, p < 0.001] and age > 65 years [HR 2.89, (95% CI) 1.56–5.33, p = 0.001]. A subgroup analysis with a minimal follow-up of 36 months revealed that Simpson III–IV [HR 3.01, 95% CI 1.31–6.931.03–1.24, p = 0.009] and age > 65 years [HR 2.48, 95% CI 1.20–5.13, p = 0.014] reduced PFS. The impact of postoperative RT on PFS remained statistically insignificant, even in a propensity-score matched survival analysis [n = 46; p = 0.438; OR 0.710 (0.299–1.687)]. Conclusions: In the present study, postoperative RT did not improve PFS. The most important prognostic factors remain the extent of resection and age.
AB - Background: Atypical meningiomas (WHO grade II) have high recurrence rate. However, data on the effect of radiotherapy (RT) is still conflicting. The aim of this study was to evaluate the influence of postoperative RT on the recurrence of primary atypical intracranial meningiomas. Methods: The medical records of all patients who underwent surgery (2007–2017 in 4 neurosurgical departments) for a histologically diagnosed primary atypical meningioma were reviewed to assess progression-free survival (PFS) and prognostic factors. Results: This analysis included 258 patients with a median age of 60 years (54.7% female). The predominant tumor locations were convexity and falx (60.9%) followed by the skull base (37.2%). Simpson grade I–II resection was achieved in 194 (75.2%) patients, Simpson grade III–IV in 53 patients (20.5%). Tumor progressed in 54 cases (20.9%). Postoperative RT was performed in 46 cases (17.8%). RT was more often applied after incomplete resection (37.7% vs. 13.4% Simpson III–IV vs. I–II). A multivariate analysis showed a significantly shorter PFS associated with Simpson III–IV [HR 1.19, (95% CI) 1.09–1.29, p < 0.001] and age > 65 years [HR 2.89, (95% CI) 1.56–5.33, p = 0.001]. A subgroup analysis with a minimal follow-up of 36 months revealed that Simpson III–IV [HR 3.01, 95% CI 1.31–6.931.03–1.24, p = 0.009] and age > 65 years [HR 2.48, 95% CI 1.20–5.13, p = 0.014] reduced PFS. The impact of postoperative RT on PFS remained statistically insignificant, even in a propensity-score matched survival analysis [n = 46; p = 0.438; OR 0.710 (0.299–1.687)]. Conclusions: In the present study, postoperative RT did not improve PFS. The most important prognostic factors remain the extent of resection and age.
KW - Atypical meningioma
KW - PFS
KW - Radiotherapy
KW - Recurrence
UR - http://www.scopus.com/inward/record.url?scp=85077261328&partnerID=8YFLogxK
U2 - 10.1007/s11060-019-03382-x
DO - 10.1007/s11060-019-03382-x
M3 - Article
C2 - 31900826
AN - SCOPUS:85077261328
SN - 0167-594X
VL - 146
SP - 347
EP - 355
JO - Journal of Neuro-Oncology
JF - Journal of Neuro-Oncology
IS - 2
ER -